● Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · G12D Mutated KRAS · Sponsor: Verastem, Inc.

PhasePhase 2

Planned participants180

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

This description comes directly from the study's public registry record.

Talk to the study team

Verastem Call Center · 7812924204 · VS-7375-201TrialSupport@verastem.com

Luke Chung, MD · VS-7375-201Medical@verastem.com

Always discuss trial participation with your own doctor first.

Locations (19)

START- Los Angeles	Los Angeles, California, United States	Recruiting
Valkyrie Clinical Trials	Los Angeles, California, United States	Recruiting
Moffitt Cancer Center	Tampa, Florida, United States	Recruiting
Johns Hopkins University	Baltimore, Maryland, United States	Recruiting
Dana-Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
START Midwest	Grand Rapids, Michigan, United States	Recruiting
Washington University	St Louis, Missouri, United States	Recruiting
START New Jersey	East Brunswick, New Jersey, United States	Recruiting
University of North Carolina	Chapel Hill, North Carolina, United States	Recruiting
Sarah Cannon Research Institute	Nashville, Tennessee, United States	Recruiting
START Dallas	Fort Worth, Texas, United States	Recruiting
MD Anderson Cancer Center	Houston, Texas, United States	Recruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07644559